Approved Drugs for Neurology
Axona (caprylidene); Accera;
For the treatment of Alzheimer's disease, Approved March 2009
Cambia (diclofenac potassium for oral solution); Kowa Pharmaceuticals;
For the treatment of migraine attacks, Approved June of 2009
Edluar (zolpidem tartrate); Orexo;
For the treatment of insomnia, Approved March 2009
Embeda (morphine sulfate and naltrexone hydrochloride); King Pharmaceuticals;
For the treatment of moderate to severe pain, Approved August of 2009
Extavia (Interferon beta-l b); Novartis;
For the treatment of relapsing multiple sclerosis, Approved August of 2009
Intuniv (guanfacine extended-release); Shire;
For the treatment of ADHD in children and adolescents, Approved September 2009
Onsolis (fentanyl buccal); BioDelivery Sciences;
For the management of breakthrough cancer pain, Approved July 2009
Sabril (vigabatrin); Lundbeck, Inc.;
For the treatment of infantile spasms and complex partial seizures, Approved August 2009
Zipsor (diclofenac potassium); Xanodyne;
For the treatment of mild to moderate acute pain, Approved June 2009
Banzel (rufinamide); Elan Pharmaceuticals;
For the treatment of seizures associated with Lennox-Gastaut syndrome in pediatrics and adults, Approved November 2008
Durezol (difluprednate); Sirion Therapeutics;
For the treatment of inflammation and pain associated with ocular surgery, Approved June 2008
Lusedra (fospropofol disodium); Elan Pharmaceuticals;
A sedative-hypnotic agent indicated for monitored anesthesia care sedation, Approved December of 2008
Stavzor (valproic acid delayed release); Banner Pharmacaps;
For the treatment of bipolar manic disorder, seizures and migraine headaches, Approved July 2008
Vimpat (lacosamide); Schwarz Pharma;
For the treatment of partial-onset seizures in adults with epilepsy, Approved October 2008
Xenazine (tetrabenazine); Prestwick Pharma;
For the treatment of chorea due to Huntington's disease, Approved August 2008
Amrix (cyclobenzaprine hydrochloride extended release); Cephalon;
For the treatment of muscle spasm associated with acute, painful musculoskeletal conditions, Approved February 2007
Exelon (rivastigmine tartrate); Novartis;
For the treatment of Alzheimer's and Parkinson's disease-related dementia, Approved July 2007
Neupro (rotigotine); Schwarz Pharma;
For the treatment of Parkinson's disease, Approved May 2007
Nuvigil (armodafinil); Cephalon;
For the treatment of excessive sleepiness, Approved June 2007
Vyvanse (Lisdexamfetamine Dimesylate); New River;
For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007
Invega (paliperidone); Janssen Pharmaceutica;
For the treatment of schizophrenia, Approved December 2006
Rozerem (ramelteon); Takeda;
For the treatment of sleep-onset insomnia, Approved July, 2005
Tysabri (natalizumab); Elan Pharmaceuticals / Biogen Idec;
For the treatment of relapsing forms of multiple sclerosis, Approved November 2004 -- Updated: Suspended February 2005--Updated: sBLA
Apokyn (apomorphine hydrochloride); Mylan Bertek Pharmaceuticals;
For the treatment of acute, intermittent hypomobility episodes associated with advanced Parkinson’s disease, Approved April, 2004
Lunesta (eszopiclone); Sepracor;
For the treatment of insomnia and sleep maintenance, Approved December 2004
Lyrica (pregabalin); Pfizer;
For the treatment of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, Approved December 2004
Cialis (tadalafil); Eli Lilly;
Oral agent for the treatment for erectile dysfunction, Approved December 2003
Levitra (vardenafil); Bayer, GlaxoSmithKline;
For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003
Namenda (memantine HCl); Forest Laboratories;
For the treatment of moderate to severe dementia of the Alzheimer’s type., Approved October 2003
Avinza (morphine sulfate); Elan Pharmaceuticals;
Extended release capsule for the relief of pain requiring continuous, around-the-clock therapy, Approved March 2002
Neurontin (gabapentin); Pfizer;
Oral treatment for the management of post-herpetic neuralgia (PHN), Approved May 2002
Rebif (interferon beta-1a); Serono Laboratories;
Subcutaneous injection for the treatment of relapsing forms of multiple sclerosis, Approved March 2002
Relpax (eletriptan hydrobromide); Pfizer;
For the acute treatment of migraine headaches, Approved December 2002
Strattera (atomoxetine HCl); Eli Lilly;
For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults., December 2002
Xyrem (sodium oxybate); Orphan Medical;
For the treatment of cataplexy, a sudden loss of muscle tone, associated with narcolepsy, Approved July 2002
Axert (almotriptan malate) tablets; Pharmacia;
For the treatment of migraine attacks, Approved May 2001
Bayer Extra Strength Asprin; Bayer;
Oral treatment for mild to moderate migraine pain, Approved October 2001
Focalin (dexmethylphenidate HCl); Celgene;
For the treatment of attention deficit hyperactivity disorder (ADHD), Approved November 2001
Frova (frovatriptan succinate); Elan Pharmaceuticals;
Tablets for the acute treatment of migraine attacks, Approved November 2001
Metadate CD; Celltech Pharmaceuticals;
Oral capsules for the treatment of attention deficit hyperactivity disorder, Approved April 2001
Reminyl (galantamine hydrobromide); Janssen Pharmaceutica;
For the treatment of mild to moderate dementia of the Alzheimer's type, Approved February 2001
Ultracet (acetaminophen and tramadol HCl); Ortho-McNeil Pharmaceutical;
For the short-term management of acute pain, Approved August 2001
Zomig (zolmitriptan); AstraZeneca;
Orally disintegrating tablet for the treatment of acute migraine in adults, Approved February 2001
Depakote ER (divalproex sodium); Abbott Laboratories;
For the prophylaxis (prevention) of migraine headaches in adults, Approved August 2000
Exelon (rivastigmine tartrate); Novartis;
Indicated for the treatment of mild to moderate dementia of the Alzheimer's type, Approved April 2000
Myobloc; Elan Pharmaceuticals;
Injectable solution for the treatment of abnormal head position and neck pain associated with cervical dystonia, Approved December 2000
Neurontin (gabapentin) oral solution; Parke-Davis;
For the treatment of partial seizures in pediatric patients three years of age and older, Approved October 2000
Neurontin (gabapentin) oral solution; Parke-Davis;
Treatment of partial seizures in adults with epilepsy, Approved March 2000
Novantrone (mitoxantrone hydrochloride); Immunex;
For reducing neurologic disability and/or the frequency of clinical relapses in patients with multiple sclerosis, Approved October 2000
Trileptal (oxcarbazepine) Tablets; Novartis;
Approved for use as adjunctive therapy in the treatment of partial seizures in children (monotherapy for adults), Approved January 2000
Zonegran (zonisamide) Capsules; Dainippon Pharmaceutical;
Adjunctive therapy for treatment of partial seizures in adults with epilepsy, Approved March 2000
Aggrenox; Boehringer Ingelheim;
Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke, Approved November 1999
Cenestin; Duramed Pharmaceuticals;
Treatment for symptoms associated with menopause, Approved July 1999
Comtan; Novartis;
200mg entacapone tablets, October 19, 1999
Keppra; UCB Pharma;
Levetiracetam tablets for adjunctive treatment of partial onset seizures in adults with epilepsy, Approved November 1999
Lamictal (lamotrigine) Chewable Dispersible Tablets; GlaxoSmithKline;
Treatment for epileptic seizures, Approved June 1999
Lidoderm Patch (lidocaine patch 5% ); Hind Health Care;
Treatment of pain in post-herpetic neuralgia, Approved June 1999
Sonata; American Home Products;
Treatment fo insomnia, Approved August 1999
Topamax (topiramate); Ortho-McNeil Pharmaceutical;
Treatment for epilepsy in pediatric patients, Approved July 1999
Amerge; GlaxoSmithKline;
Treatment for acute migraine, Approved February 1998
Clonazepam; Watson Pharmaceuticals;
Generic equivalent of Klonopin, Approved January 1998
Cylert; Abbott Laboratories;
Treatment for Attention Deficit Disorder, Approved October 1998
Excedrin Migraine; Bristol-Myers Squibb;
Treatment for mild to moderate migraine pain, Approved January 1998
Lamictal Chewable Dispersible Tablets; GlaxoSmithKline;
Treatment for Epilepsy, Approved August 1998
Maxalt; Merck;
Acute treatment of migraine headache, Approved June 1998
Naltrexone Hydrochloride Tablets; Barr Laboratories;
Generic equivalent of Revia, Approved May 1998
Oxycodone and Aspirin; Watson Pharmaceuticals;
Generic equivalent of Percodan, Approved March 1998
Tasmar; Roche;
Treatment for Parkinson's Disease, Approved January 1998
Bromfenac; Duract, Wyeth-Ayerst Laboratories;
Management of acute pain, Approved July 1997
Carbatrol; Elan Pharmaceuticals;
Treatment for epileptic seizures and trigeminal neuralgia, Approved September 1997
Copaxone; Teva Pharmaceutical;
Treatment for relapsing-remitting multiple sclerosis, Approved January 1997
Galzin (zinc acetate); Teva Pharmaceutical;
Treatment for Wilson’s disease, Approved January 1997
Imitrex (sumatriptan) injection and tablets; GlaxoSmithKline;
Treatment for migraine headaches, Approved August 1997
Imitrex (sumatriptan) nasal spray; GlaxoSmithKline;
Treatment for migraine, Approved November 1997
Migranal; Novartis;
Treatment for migraine headaches, Approved December 1997
Mirapex; Pharmacia & Upjohn, Boehringer Ingelheim;
Treatment for Parkinson’s Disease, Approved June 1997
NORCO tablets (Hydrocodone Bitartrate/Acetaminophen 10 mg/325 mg); Watson Pharmaceuticals;
Treatment for moderate to moderately severe pain, Approved February 1997
Oxycodone with Acetaminophen 5mg/325mg; Watson Pharmaceuticals;
Generic equivalent of Percocet and Tylox, Approved November 1997
Pramipexole; Pharmacia & Upjohn;
Treatment for Parkinson's Disease, Approved July 1997
Quadramet (Samarium Sm 153 Lexidronam Injection); DuPont Merck Pharmaceutical Company;
Treatment for pain associated with bone cancer, Approved March 1997
Requip (ropinirole hydrochloride); SmithKline Beecham;
Treatment for Parkinson's Disease, Approved September 1997
Selegiline tablets; Teva Pharmaceutical;
Generic equivalent of Eldepryl tablets, Approved January 1997
Topamax (topiramate); Ortho-McNeil Pharmaceutical;
Treatment for partial onset seizures, Approved January 1997
VERSED (midazolam HCI); Roche;
Treatment for sedating children who must undergo painful surgery, Approved March 1997
Zomig (zolmitriptan); AstraZeneca;
Treatment for migraine, Approved November 1997
Anexsia; Mallinckrodt Group;
Treatment for chronic pain, Approved August 1996
ARICEPT (donepezil hydrochloride); Eisai;
Treatment for Alzheimer's Disease, Approved December 1996
Depakote (divalproex sodium); Abbott Laboratories;
Treatment for epilepsy, Approved June 1996
Depakote (divalproex sodium); Abbott Laboratories;
Treatment for migraine headaches, Approved March 1996
Iontocaine; Iomed;
Needle-free anesthetic, Approved May 1996
Kadian; Purepac Pharmaceutical;
Treatment for chronic moderate to severe pain, Approved July 1996
Merrem I.V. (meropenem); AstraZeneca;
Treatment for intra-abdominal infections and bacterial meningitis, Approved June 1996
Redux (dexfenfluramine hydrochloride); Wyeth;
Treatment for obesity, Approved May 1996
Tegretol (carbamazepine); Ciba Pharmaceuticals;
Treatment for young children with epilepsy, Approved March 1996
Tegretol XR (carbamazepine); Ciba-Geigy;
Anti-epileptic treatment, Approved May 1996
UltraJect; Mallinckrodt Group;
Treatment for chronic pain, Approved August 1996
Visipaque (iodixanol); Nycomed;
Diagnostic contrast agent, Approved April 1996
Zanaflex (tizanidine hydrochloride); Elan Pharmaceuticals;
Treatment for muscle spasticity, Approved December 1996
Avonex (Interferon Beta 1-A); Biogen IDEC;
Treatment for multiple sclerosis, Recommended for Approval in December 1995
Rilutek (riluzole); Rhone Poulenc Rorer;
Treatment for amyotrophic lateral sclerosis (ALS), Approved December 1995
